查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1989944

肛门癌市场：2026-2032年全球市场预测（依治疗方法、最终用户、治疗线、分期、给药途径、癌症类型和分销管道划分）

Anal Cancer Market by Treatment Type, End User, Therapeutic Line, Disease Stage, Administration Mode, Cancer Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肛门癌市场价值将达到 11.3 亿美元，到 2026 年将成长到 12 亿美元，到 2032 年将达到 17.7 亿美元，复合年增长率为 6.59%。

主要市场统计数据
基准年 2025 11.3亿美元
预计年份：2026年 12亿美元
预测年份 2032 17.7亿美元
复合年增长率 (%) 6.59%

清晰权威地指南肛门癌的最新临床进展、不断发展的护理路径以及影响肛门癌诊断和治疗的策略重点。

免疫肿瘤学、精准诊断和多方面治疗方法的进步，已使肛门癌从相对专业的临床难题转变为跨学科研究的重点。近年来，随着临床医生在局部控制和器官保留之间寻求平衡，治疗流程也日益复杂，全身性治疗选择也扩展到传统细胞毒性药物之外。因此，临床实践、临床研发和医疗政策领域的相关人员需要对影响患者预后和资源分配的治疗方法、诊断创新以及医疗服务体系变革进行简明扼要的概述。

分子诊断、免疫疗法整合以及医疗保健服务体系的重新设计如何改变肛门癌的治疗途径和商业策略。

肛门癌的治疗格局正在经历一场变革性的转变，这主要得益于分子层面的深入研究、治疗方法的出现以及以患者为中心的医疗服务模式的重新兴起。免疫疗法正从一项前景广阔的研究阶段治疗方法，逐步应用于特定患者群体，这促使人们重新评估与现有放化疗放射线治疗相比的治疗顺序和联合治疗策略。同时，放射治疗技术和治疗计划的进步使得剂量传递更加精准，从而降低了毒性，促进了器官保留，并影响了转诊模式。

2025 年的收费系统要求供应链具备韧性，采购结构进行重组，并采取适应性合约措施，以维持治疗和临床运作的正常进行。

美国于2025年实施的费用调整为肛门癌治疗领域的相关人员引入了新的变量，包括供应链、医疗设备采购以及依赖进口的药品。短期内，某些专用设备和试剂进口成本的增加迫使采购团队和医院药局调整其采购政策。因此，采购方尽可能地转向国内供应商，并加快了与替代供应商的谈判。这种情况也凸显了放射治疗组件、诊断试剂盒和肠外给药等易受跨境物流影响的药品供应链规划的重要性。

从详细的细分观点揭示治疗方法、医疗保健环境和交付管道如何影响临床决策和商业性定位。

細項分析揭示了治疗方法方案、临床环境、治疗线、疾病分期、给药途径、癌症组织学类型和分销管道如何为相关人员建立不同的决策路径。在整体治疗方法中，传统化疗仍然是基础，单药治疗和联合治疗则应用于特定的临床情境，而同步和序贯放射线治疗等联合治疗放射线治疗在平衡肿瘤控制和功能预后方面发挥核心作用。手术方案包括腹会阴联合切除术和局部切除术，具体选择取决于肿瘤范围、患者意愿和挽救性治疗的考虑因素。免疫疗法（例如查核点抑制剂和疫苗策略）以及标靶治疗（例如 EGFR 抑制剂）正在影响晚期治疗策略和临床试验设计。

对全球市场肛门癌治疗的临床模式、监管环境和进入因素进行区域比较分析。

区域趋势正对美洲、欧洲、中东和非洲以及亚太地区的临床实践模式、报销标准和临床试验生态系统产生重大影响。在美洲，整合的肿瘤网络和完善的临床试验基础设施正在促进变革性证据的快速应用，并支持复杂的联合治疗。同时，支付方的多样性要求制定细緻入微的准入策略，以兼顾公共和私人报销机制。许多医疗机构正在转向基于价值的讨论，这正在改变药物应用谈判和患者管理的优先事项。

临床中心、诊断技术创新者和商业伙伴之间的合作如何加速肛门癌治疗方法的开发和市场化。

这种竞争与合作并存的环境涵盖了生物製药创新者、诊断公司、合约研究组织 (CRO) 以及专注于药物递送和放射治疗计划的医疗设备製造商。领先的临床研究人员和学术机构持续透过研究者主导的临床试验和多中心试验来推动实证医学的产生，这些试验旨在评估联合治疗、新型免疫疗法和基于生物标记的方法。诊断服务提供者正在改进分子诊断和病理工作流程，以更深入地了解肿瘤的生物学特征，从而支持更具选择性的患者招募和伴随诊断策略。

为产业领导者提供切实可行的策略，以协调临床开发、支付方合作和供应链韧性，从而在肛门癌领域取得可持续的商业性成功。

业界领导企业可以透过将临床开发与新的护理标准结合，并投资于能够展现真实世界疗效和价值的数据策略，来增强其竞争优势。优先进行将生物标记定义的患者群体与治疗结果联繫起来的后期转化研究，可以简化临床实验，并在市场中脱颖而出。此外，将商业化准备计划与支付方的证据要求和医疗服务提供者的工作流程考虑相结合，可以减少市场上市的障碍，并支持可持续的市场渗透。

我们采用透明、多方面的研究途径，结合临床证据评估、专家访谈和相关人员的三角检验，得出可操作的策略见解。

本分析的调查方法整合了同行评审的临床文献、监管指南、临床专家访谈以及来自支付方和医疗服务提供者等相关人员的定性信息，从而构建出治疗、诊断和交付趋势的全面图景。数据三角验证确保临床结论是基于检验的资讯来源，而与专家的咨询则提供了关于实践差异和营运考虑的背景资讯。必要时，对治疗路径和相关利益者奖励的比较分析揭示了其对产品开发和商业化的实际意义。

整合临床进展、诊断技术改进和营运准备，将指导肛门癌的策略决策，并改善以患者为中心的治疗效果。

总之，肛门癌领域正日益成熟，成为一个复杂的多学科交叉领域，治疗创新、诊断技术改进和医疗服务模式不断发展交织融合，共同影响着患者的治疗效果和商业性前景。相关人员必须应对这样一种环境：免疫疗法和标靶治疗正逐步融入现有的放射线治疗方案，诊断技术助力患者筛选，而区域间医疗实践的差异则影响着患者的就医途径和临床试验的设计。成功的专案会预见这些变化，将临床开发与实际应用相结合，建立能够引起保险公司和医疗服务提供者共鸣的证据，并确保整个供应链和分销管道拥有稳健的营运体系。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肛门癌市场：依治疗方法

  • 化疗
  • 联合治疗
    • 放射线治疗
    • 序贯放射线治疗
  • 免疫疗法
    • 查核点抑制剂
    • 疫苗疗法
  • 放射线治疗
    • 近距离放射治疗
    • 体外放射治疗
  • 外科手术
    • 腹会阴联合切除术
    • 局部切除

第九章：肛门癌市场：依最终用户划分

  • 门诊手术中心
  • 诊断检查室
  • 医院
  • 肿瘤中心
  • 专科诊所

第十章：肛门癌市场：依治疗方案划分

  • 第 1 行
  • 第二行
  • 从第三行开始

第十一章：肛门癌市场：依分期划分

  • 第三阶段
  • 第四阶段
  • 第一阶段-第二阶段

第十二章：肛门癌市场：依给药途径划分

  • 静脉
  • 口服
  • 外用

第十三章：肛门癌市场：依癌症类型划分

  • 腺癌
  • 恶性黑色素瘤
  • 鳞状细胞癌

第十四章：肛门癌市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十五章：肛门癌市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：肛门癌市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 肛门癌市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国：肛门癌市场

第十九章 中国：肛门癌市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accuray Incorporated
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardinal Health, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Elekta AB
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • IBA Worldwide
  • McKesson Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Siemens Healthineers AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.
  • ViewRay Technologies, Inc.
Product Code: MRR-CD5A9334D00D

The Anal Cancer Market was valued at USD 1.13 billion in 2025 and is projected to grow to USD 1.20 billion in 2026, with a CAGR of 6.59%, reaching USD 1.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.13 billion
Estimated Year [2026] USD 1.20 billion
Forecast Year [2032] USD 1.77 billion
CAGR (%) 6.59%

A clear and authoritative orientation to recent clinical advances, evolving care pathways, and strategic priorities shaping anal cancer practice and research

Anal cancer has evolved from a relatively specialized clinical concern to a focal point of multidisciplinary research, owing to advances in immuno-oncology, precision diagnostics, and refinements in multimodal therapy. Over recent years, treatment algorithms have become more nuanced as clinicians balance local control with organ preservation, and as systemic options expand beyond conventional cytotoxic agents. Consequently, stakeholders across clinical practice, clinical development, and health policy require concise synthesis of therapeutic developments, diagnostic innovations, and service delivery changes that influence patient outcomes and resource allocation.

This executive summary distills the core trends shaping clinical practice and commercial strategy for anal cancer, contextualizing therapeutic innovations alongside care pathway shifts and regional practice variation. It highlights the interplay between established modalities such as chemoradiotherapy and surgery and emergent classes like checkpoint inhibitors and targeted approaches. Moreover, it frames how diagnostic refinements and administration modes influence treatment selection and patient experience. The goal is to equip decision-makers with a clear, actionable perspective that supports clinical program planning, vendor assessment, and research prioritization.

How molecular diagnostics, immunotherapy integration, and care delivery redesign are reshaping treatment pathways and commercial strategies in anal cancer

The landscape of anal cancer care is undergoing transformative shifts driven by molecular insights, therapeutic innovation, and a renewed emphasis on patient-centric delivery models. Immunotherapy has moved from investigational promise toward broader integration in certain patient cohorts, prompting re-evaluation of sequencing and combination strategies relative to established chemoradiotherapy approaches. Concurrently, improvements in radiotherapy technology and planning are enabling more precise dose delivery, which reduces toxicity and supports organ preservation, thereby influencing surgical referral patterns.

In parallel, diagnostic capabilities have improved, with molecular profiling and advanced pathology techniques clarifying histologic subtypes and potential actionable targets. These diagnostics are precipitating a shift from one-size-fits-all protocols toward more tailored regimens informed by tumor biology and patient factors. Additionally, the care landscape is becoming more distributed: oncology centers, ambulatory surgical centers, and specialty clinics are sharing responsibilities in ways that enhance access but require new coordination models. Taken together, these shifts demand that clinical leaders and commercial teams rethink trial designs, market access approaches, and provider engagement strategies to remain aligned with the evolving standard of care.

The 2025 tariff environment compelled supply chain resilience, procurement realignment, and adaptive contracting to sustain therapy access and clinical operations

Tariff changes implemented in 2025 across the United States introduced new variables for supply chains, device procurement, and import-dependent therapeutics that are relevant to stakeholders involved in anal cancer care. In the short term, procurement teams and hospital pharmacies have faced adjustments in sourcing decisions as import costs for certain specialized equipment and reagents rose, prompting shifts toward domestic suppliers where available and accelerated negotiations with alternate vendors. This environment has also underscored the importance of resilient supply chain planning for radiotherapy components, diagnostic kits, and parenteral therapies that are sensitive to cross-border logistics.

Over the medium term, manufacturers and distributors have responded by diversifying manufacturing footprints and reviewing pricing strategies to mitigate tariff-driven cost pressure. Payer and provider contract negotiations increasingly factor in these input-cost dynamics, affecting formulary placement discussions and purchasing cycles. For clinical trial operations, tariff-related supply chain constraints have necessitated contingency planning to ensure continuity of investigational drug supply and equipment availability at participating sites. Overall, the 2025 tariff environment emphasized the need for strategic sourcing, flexible contracting, and proactive stakeholder communication to protect treatment continuity and clinical development timelines.

Detailed segmentation-driven perspectives revealing how therapeutic modalities, care settings, and delivery channels shape clinical decision-making and commercial positioning

Segmentation analysis reveals how treatment choices, care settings, therapeutic lines, disease staging, administration modes, cancer histology, and distribution channels create distinct decision-making pathways for stakeholders. Across treatment types, conventional chemotherapy remains foundational, with single-agent and combination regimens applied in defined clinical contexts, while combined modality approaches such as concurrent and sequential chemoradiotherapy are central to balancing tumor control with functional outcomes. Surgical options span abdominoperineal resection and local excision, with selection guided by tumor extent, patient preference, and salvage considerations. Immunotherapy, delineated by checkpoint inhibitors and vaccine strategies, and targeted approaches such as EGFR inhibitors, are influencing late-line strategies and trial design.

End users shape uptake and delivery models: ambulatory surgical centers and specialty clinics often facilitate minimally invasive procedures and follow-up care, while diagnostic laboratories, both molecular and traditional pathology services, underpin treatment personalization and staging decisions. Hospitals, including community and tertiary settings, remain pivotal for complex multimodality care and inpatient management. Therapeutic line segmentation highlights different clinical priorities across first-line approaches that combine chemoradiotherapy and radiotherapy alone, second-line choices where chemotherapy, immunotherapy, and targeted therapies compete, and later-line pathways that often rely on clinical trials and palliative strategies. Disease stage stratification into early and advanced categories determines aggressiveness of local therapy and systemic options. Administration mode distinctions-intravenous, oral, topical-affect patient convenience, adherence considerations, and care setting logistics. Histologic subtypes such as adenocarcinoma, melanoma-related presentations, and squamous cell carcinoma present unique biological behaviors that influence both diagnostic workflows and therapeutic targeting. Finally, distribution channels spanning hospital, online, and retail pharmacy networks shape access, dispensing practices, and patient support services. Integrating these segmentation lenses enables more granular product positioning, clinical trial cohort definition, and value communication tailored to distinct stakeholder needs.

A comparative regional analysis of practice patterns, regulatory landscapes, and access considerations shaping anal cancer care across global markets

Regional dynamics influence clinical practice patterns, reimbursement norms, and trial ecosystems in meaningful ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated oncology networks and established clinical trial infrastructures facilitate rapid adoption of practice-changing evidence and support complex multimodality care, while payer diversity necessitates nuanced access strategies that account for public and private reimbursement mechanisms. Transitioning to value-based discussions is underway in many centers, which alters formulary negotiation and patient management priorities.

Across Europe, Middle East & Africa, regulatory environments and health system organization vary substantially, driving heterogeneity in access to advanced diagnostics and novel therapies. In Western European systems, centralized HTA assessments and multidisciplinary tumor boards often accelerate evidence translation, whereas resource constraints in other parts of the region lead to more conservative adoption patterns and reliance on surgical or radiotherapy-centered approaches. The Asia-Pacific region presents a mix of high-capacity tertiary centers and rapidly expanding oncology services, with strong interest in localized manufacturing and regional clinical development partnerships. Variations in disease epidemiology, patient demographics, and care delivery infrastructures across these regions shape clinical trial enrollment strategies, real-world evidence generation priorities, and commercialization roadmaps. Appreciating and planning for these regional nuances is essential for effective stakeholder engagement and sustainable program implementation.

How collaboration among clinical centers, diagnostics innovators, and commercial partners is accelerating therapeutic development and market entry in anal cancer

The competitive and collaborative landscape includes biopharmaceutical innovators, diagnostics developers, contract research organizations, and specialized device manufacturers focused on therapeutic delivery and radiation planning. Leading clinical investigators and academic centers continue to drive evidence generation through investigator-initiated studies and multicenter trials that evaluate combination regimens, novel immunotherapies, and biomarker-driven approaches. Diagnostic providers are enhancing molecular and pathology workflows to better characterize tumor biology, which supports more selective patient enrollment and companion diagnostic strategies.

Commercial actors are increasingly partnering across the value chain to accelerate clinical development and market entry, combining clinical expertise with distribution networks and payer engagement capabilities. Smaller companies with niche technologies are attractive partners for larger firms seeking to expand portfolios or fill therapeutic gaps. Additionally, service providers that offer trial operations, real-world evidence collection, and health economics expertise are gaining prominence as sponsors seek to demonstrate value and support reimbursement submissions. These dynamics indicate a collaborative ecosystem where strategic alliances, licensing agreements, and co-development models will play a central role in advancing therapeutic options and improving patient outcomes.

Actionable strategies for industry leaders to align clinical development, payer engagement, and supply chain resilience for sustained commercial success in anal cancer

Industry leaders can sharpen competitive advantage by aligning clinical development with emerging standards of care and by investing in data strategies that demonstrate real-world effectiveness and value. Prioritizing late-stage translational research that links biomarker-defined populations to therapeutic outcomes will improve trial efficiency and market differentiation. Moreover, aligning commercial readiness plans with payer evidence requirements and provider workflow considerations will reduce barriers at launch and support sustainable uptake.

Operationally, building resilient supply chains and flexible manufacturing partnerships will mitigate external shocks and tariff-related uncertainties. Engaging early with multidisciplinary clinical stakeholders and patient advocacy groups will surface unmet needs and inform pragmatic trial endpoints that resonate with both clinicians and payers. Finally, offering comprehensive support services-such as adherence programs, diagnostic enablement, and educational initiatives for providers-will strengthen value propositions and foster long-term adoption of new therapies.

A transparent, multi-source research approach combining clinical evidence appraisal, expert interviews, and stakeholder triangulation to derive actionable strategic insights

The research methodology underpinning this analysis synthesizes peer-reviewed clinical literature, regulatory guidance, expert clinician interviews, and qualitative inputs from payer and provider stakeholders to construct an integrated view of therapeutic, diagnostic, and delivery trends. Data triangulation ensures that clinical assertions are grounded in validated sources, while expert consultations provide context on practice variability and operational considerations. Where appropriate, comparative analyses of treatment pathways and stakeholder incentives were conducted to surface practical implications for product development and commercialization.

Attention was paid to methodological transparency: inclusion criteria for literature, selection rationale for expert informants, and the approach to regional comparison were documented to support reproducibility. Bias mitigation strategies included cross-referencing multiple sources, soliciting divergent expert perspectives, and treating emerging signals with appropriate caveats until corroborated. The resulting synthesis emphasizes qualitative insights and actionable interpretation rather than quantitative extrapolation, ensuring conclusions are applicable to strategic decision-making in clinical development and commercial planning.

Synthesizing clinical evolution, diagnostic advances, and operational readiness to guide strategic decision-making and enhance patient-centered outcomes in anal cancer

In conclusion, the anal cancer landscape is maturing into a complex, multidisciplinary arena where therapeutic innovation, diagnostic refinement, and delivery model evolution converge to influence patient outcomes and commercial prospects. Stakeholders must navigate an environment where immunotherapy and targeted approaches are progressively integrated with established chemoradiotherapy regimens, diagnostics increasingly enable patient selection, and regional practice variation shapes access and trial design. Successful programs will be those that anticipate these shifts by aligning clinical development with real-world practice, building evidence that resonates with payers and providers, and ensuring operational readiness across supply chains and distribution channels.

Moving forward, organizations that combine scientific rigor with pragmatic commercialization planning and proactive stakeholder engagement will be best positioned to translate therapeutic advances into meaningful clinical and economic value. Embracing collaborative models and investing in adaptive trial designs and evidence-generation frameworks will accelerate the path from innovation to standard practice, ultimately improving patient outcomes in this challenging disease space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anal Cancer Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Combined Modality Therapy
    • 8.2.1. Concurrent Chemoradiotherapy
    • 8.2.2. Sequential Chemoradiotherapy
  • 8.3. Immunotherapy
    • 8.3.1. Checkpoint Inhibitors
    • 8.3.2. Vaccine Therapy
  • 8.4. Radiotherapy
    • 8.4.1. Brachytherapy
    • 8.4.2. External Beam Radiotherapy
  • 8.5. Surgery
    • 8.5.1. Abdominoperineal Resection
    • 8.5.2. Local Excision

9. Anal Cancer Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals
  • 9.4. Oncology Centers
  • 9.5. Specialty Clinics

10. Anal Cancer Market, by Therapeutic Line

  • 10.1. First-Line
  • 10.2. Second-Line
  • 10.3. Third-Line And Beyond

11. Anal Cancer Market, by Disease Stage

  • 11.1. Stage III
  • 11.2. Stage IV
  • 11.3. Stage I-II

12. Anal Cancer Market, by Administration Mode

  • 12.1. Intravenous
  • 12.2. Oral
  • 12.3. Topical

13. Anal Cancer Market, by Cancer Type

  • 13.1. Adenocarcinoma
  • 13.2. Melanoma
  • 13.3. Squamous Cell Carcinoma

14. Anal Cancer Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Anal Cancer Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Anal Cancer Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Anal Cancer Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Anal Cancer Market

19. China Anal Cancer Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Accuray Incorporated
  • 20.6. Amgen Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Bayer AG
  • 20.9. Bristol-Myers Squibb Company
  • 20.10. Cardinal Health, Inc.
  • 20.11. Dr. Reddy's Laboratories Ltd.
  • 20.12. Elekta AB
  • 20.13. Eli Lilly and Company
  • 20.14. Fresenius Kabi AG
  • 20.15. GlaxoSmithKline PLC
  • 20.16. Hikma Pharmaceuticals PLC
  • 20.17. IBA Worldwide
  • 20.18. McKesson Corporation
  • 20.19. Merck & Co., Inc.
  • 20.20. Novartis AG
  • 20.21. Pfizer Inc.
  • 20.22. Roche Holding AG
  • 20.23. Sanofi S.A.
  • 20.24. Siemens Healthineers AG
  • 20.25. Sun Pharmaceutical Industries Ltd.
  • 20.26. Teva Pharmaceutical Industries Ltd.
  • 20.27. Varian Medical Systems, Inc.
  • 20.28. ViewRay Technologies, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANAL CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANAL CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANAL CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANAL CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANAL CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANAL CANCER MARKET SIZE, BY CONCURRENT CHEMORADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANAL CANCER MARKET SIZE, BY CONCURRENT CHEMORADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANAL CANCER MARKET SIZE, BY CONCURRENT CHEMORADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANAL CANCER MARKET SIZE, BY SEQUENTIAL CHEMORADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANAL CANCER MARKET SIZE, BY SEQUENTIAL CHEMORADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANAL CANCER MARKET SIZE, BY SEQUENTIAL CHEMORADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANAL CANCER MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANAL CANCER MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANAL CANCER MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANAL CANCER MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANAL CANCER MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANAL CANCER MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANAL CANCER MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANAL CANCER MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANAL CANCER MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANAL CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANAL CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANAL CANCER MARKET SIZE, BY ABDOMINOPERINEAL RESECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANAL CANCER MARKET SIZE, BY ABDOMINOPERINEAL RESECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANAL CANCER MARKET SIZE, BY ABDOMINOPERINEAL RESECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANAL CANCER MARKET SIZE, BY LOCAL EXCISION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANAL CANCER MARKET SIZE, BY LOCAL EXCISION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANAL CANCER MARKET SIZE, BY LOCAL EXCISION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANAL CANCER MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANAL CANCER MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANAL CANCER MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANAL CANCER MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANAL CANCER MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANAL CANCER MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANAL CANCER MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANAL CANCER MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANAL CANCER MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANAL CANCER MARKET SIZE, BY THIRD-LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANAL CANCER MARKET SIZE, BY THIRD-LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANAL CANCER MARKET SIZE, BY THIRD-LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE I-II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE I-II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE I-II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANAL CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANAL CANCER MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANAL CANCER MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANAL CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANAL CANCER MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANAL CANCER MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANAL CANCER MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANAL CANCER MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANAL CANCER MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANAL CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANAL CANCER MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANAL CANCER MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANAL CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANAL CANCER MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANAL CANCER MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANAL CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. G7 ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. G7 ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 268. G7 ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. NATO ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 279. NATO ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 280. NATO ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. NATO ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)